MedTrace Logo

VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation

NCT04452669 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-07-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.

Conditions

Interventions

DRUG

VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)

VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.

Sponsors & Collaborators

  • Ohio State University

    collaborator OTHER

  • Aerogen Pharma Limited

    lead INDUSTRY

Principal Investigators

  • Veronica Franco, MD · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2021-06-29
Completion
2021-06-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04452669 on ClinicalTrials.gov